Literature DB >> 21979376

Brain iron dysregulation and the risk of ageing white matter lesions.

Ola H Gebril1, J E Simpson, Janine Kirby, Carol Brayne, Paul G Ince.   

Abstract

White matter lesions (WML) or leukoaraiosis is a major feature in cerebral imaging of older people, and their prevalence increases with age. The clinical effects of WML vary with the main impairment being detected in the cognitive functions, increased risk of severe depression and motor impairment. Although vascular comorbidities have been found to be the main changes in these brains, increased production of reactive oxygen species (ROS) could represent a risk factor for these lesions with elemental iron being a potential factor for ROS production. This study focuses on changes in iron, iron-regulating proteins and RNA expression of iron metabolism genes. Three groups of samples were used: WML, normal areas from lesional WM [NAWM (L)] as disease control and normal WM from control brains [NAWM(C)]. Ferric iron staining was undertaken using known Perl's reaction. Immunohistochemistry (IHC) of white matter for ceruloplasmin (Cp), haemochromatosis (HFE) and transferrin receptor (TfR) was done. Cellular localization of HFE and Cp was performed using dual-antibody IHC. Whole-genome RNA was extracted from WML, NAWM (L) and NAWM(C), and QPCR for HFE, TF, TfR, ceruloplasmin, ferritin and ferroportin was performed. Ferric iron staining shows increased diffuse iron staining among WML, followed by NAWM (L) and the least group being NAWM(C). IHC shows increased HFE and CP expression in lesional WM, while TfR shows no changes among the groups. HFE colocalized with vascular endothelium and microglia in WML and control samples, while Cp colocalized with microglia and some expression was shown by astrocytes. The mRNA expression using QPCR suggests a pattern that favours decreased intracellular iron influx, increased ferrous oxidation and increased iron export from the cells. Iron metabolism seems to be changed in brains with WML, increased elemental iron in these brains and in turn increased production of free oxidative radicals could represent a potentiating factor for the development of ageing WML.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21979376     DOI: 10.1007/s12017-011-8161-y

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  36 in total

1.  HFE mutations are not strongly associated with sporadic ALS.

Authors:  A A Yen; E P Simpson; J S Henkel; D R Beers; S H Appel
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

2.  Crystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptor.

Authors:  M J Bennett; J A Lebrón; P J Bjorkman
Journal:  Nature       Date:  2000-01-06       Impact factor: 49.962

3.  Cognitive correlates of brain MRI subcortical signal hyperintensities in non-demented elderly.

Authors:  Gad A Marshall; Rick Hendrickson; Daniel I Kaufer; Larry S Ivanco; Nicolaas I Bohnen
Journal:  Int J Geriatr Psychiatry       Date:  2006-01       Impact factor: 3.485

Review 4.  Oxidative stress and neurodegeneration: where are we now?

Authors:  Barry Halliwell
Journal:  J Neurochem       Date:  2006-06       Impact factor: 5.372

Review 5.  Oxygen toxicity, oxygen radicals, transition metals and disease.

Authors:  B Halliwell; J M Gutteridge
Journal:  Biochem J       Date:  1984-04-01       Impact factor: 3.857

6.  Age-related microvascular degeneration in the human cerebral periventricular white matter.

Authors:  Eszter Farkas; Rob A I de Vos; Gergely Donka; E N Jansen Steur; András Mihály; Paul G M Luiten
Journal:  Acta Neuropathol       Date:  2006-02-02       Impact factor: 17.088

7.  The distribution of iron in the brain: a phylogenetic analysis using iron histochemistry.

Authors:  G L Erb; D L Osterbur; S M LeVine
Journal:  Brain Res Dev Brain Res       Date:  1996-05-31

8.  Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study.

Authors:  M M Breteler; J C van Swieten; M L Bots; D E Grobbee; J J Claus; J H van den Hout; F van Harskamp; H L Tanghe; P T de Jong; J van Gijn
Journal:  Neurology       Date:  1994-07       Impact factor: 9.910

Review 9.  Iron dyshomeostasis in Parkinson's disease.

Authors:  J Salazar; N Mena; M T Núñez
Journal:  J Neural Transm Suppl       Date:  2006

10.  Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases.

Authors:  Marie-Catherine Boll; Mireya Alcaraz-Zubeldia; Sergio Montes; Camilo Rios
Journal:  Neurochem Res       Date:  2008-02-29       Impact factor: 3.996

View more
  5 in total

1.  Iron-regulatory genes are associated with Neuroimaging measures in HIV infection.

Authors:  Christine Fennema-Notestine; Tricia A Thornton-Wells; Todd Hulgan; Scott Letendre; Ronald J Ellis; Donald R Franklin; Albert M Anderson; Robert K Heaton; Cinnamon S Bloss; Igor Grant; Asha R Kallianpur
Journal:  Brain Imaging Behav       Date:  2020-10       Impact factor: 3.978

2.  Brain iron deposition in white matter hyperintensities: a 3-T MRI study.

Authors:  Shenqiang Yan; Jianzhong Sun; Yi Chen; Magdy Selim; Min Lou
Journal:  Age (Dordr)       Date:  2012-11-07

3.  Age-associated white matter lesions: the MRC Cognitive Function and Ageing Study.

Authors:  Stephen B Wharton; Julie E Simpson; Carol Brayne; Paul G Ince
Journal:  Brain Pathol       Date:  2015-01       Impact factor: 6.508

4.  Naotaifang extract treatment results in increased ferroportin expression in the hippocampus of rats subjected to cerebral ischemia.

Authors:  Jun Liao; Xing Xia; Guo-Zuo Wang; Yong-Mei Shi; Jin-Wen Ge
Journal:  Mol Med Rep       Date:  2015-02-06       Impact factor: 2.952

Review 5.  Iron metabolism in diabetes-induced Alzheimer's disease: a focus on insulin resistance in the brain.

Authors:  Ji Yeon Chung; Hyung-Seok Kim; Juhyun Song
Journal:  Biometals       Date:  2018-07-24       Impact factor: 2.949

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.